A study explored if stopping antidepressants during pregnancy affects the risk of PPHN, hospitalization, and congenital heart defects.| Pulmonary Hypertension News
The Web's Daily Resource for PH News| Pulmonary Hypertension News
Higher pulmonary arterial pressure in pregnant women with PH was linked to longer hospitalizations, and ICU admission, in a long-term study.| Pulmonary Hypertension News
Read about Sildenafil citrate, another potent vasodilator for use among PAH patients.| Pulmonary Hypertension News
Patients and clinicians endorsed Opsynvi as a single-tablet combination therapy for PAH in interviews conducted during a clinical trial.| Pulmonary Hypertension News
Low-dose metformin delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of PAH in rats.| Pulmonary Hypertension News
Read about adcirca, a phosphodiesterase 5 inhibitor, another mechanism of slowing down disease progression in pulmonary hypertension patients| Pulmonary Hypertension News
Corvista Health’s point-of-care device can detect cases of PH that other testing methods miss, according to a recent case series.| Pulmonary Hypertension News
While PH Awareness Month is a great opportunity to connect and educate, rare disease advocacy is columnist Jen Cueva's passion all year.| Pulmonary Hypertension News
Columnist Colleen Steele took a break from writing after her husband passed away in 2023, but she's ready to keep raising PH awareness.| Pulmonary Hypertension News
Esteban holds a Master of Science in Immunology from the Instituto Politécnico Nacional in Mexico, focused on inflammation and metabolism. With five years of experience as a Medical Science Liaison, he has worked directly with physicians across a wide range of specialties, covering topics...| Pulmonary Hypertension News
PH patients face barriers to timely care from symptom onset through treatment and follow-up, a study found.| Pulmonary Hypertension News
A 68-year-old man with severe PAH and multiple coexisting conditions experienced marked improvement after receiving combination therapy.| Pulmonary Hypertension News
Learn more about pulmonary hypoxic hypertension, which is caused by a shortage of oxygen in the body (hypoxia), and classified as a type of group 3 pulmonary hypertension by the World Health Organization (WHO).| Pulmonary Hypertension News
Exosomes released by mesenchymal stem cells may help reduce vascular remodeling and ease PH symptoms, a rat study showed.| Pulmonary Hypertension News
LungFit PH, Beyond Air's nitric oxide therapy device, has received the European CE mark approval for pulmonary hypertension in newborns.| Pulmonary Hypertension News
Steve Bryson is a science writer for Pulmonary Hypertension News with a PhD in biochemistry. He covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
Read about the different classes of the World Health Organization's (WHO) Pulmonary Hypertension Functional Classification.| Pulmonary Hypertension News
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
The U.S. FDA has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for treating pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
The FDA has approved the use of Cereno Scientific’s CS1 in an extension of the ongoing Phase 2 trial testing the therapy in people with PAH.| Pulmonary Hypertension News
After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in PH-ILD patients.| Pulmonary Hypertension News
A 5-year-old boy with a neuroblastoma developed PAH after receiving a high dose of chemotherapy to prepare for a stem cell transplant.| Pulmonary Hypertension News
Marisa Wexler is a senior science writer for Pulmonary Hypertension News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
No description.| Pulmonary Hypertension News
Corvista Health’s point-of-care device, used to predict pulmonary hypertension (PH), also appears to work well at identifying heart failure.| Pulmonary Hypertension News
The FDA granted breakthrough device designation to CorVista for its system diagnosing pulmonary hypertension and cardiovascular disorders.| Pulmonary Hypertension News
Margarida Maia is a science writer for Pulmonary Hypertension News with a PhD in biomedical sciences. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
The Aeson Total Artificial Heart helped three people with heart failure and pulmonary hypertension become eligible for a heart transplant.| Pulmonary Hypertension News
The immune protein STAT6 may be a driver of pulmonary hypertension in people with obstructive sleep apnea, a study in mice suggests.| Pulmonary Hypertension News
Researchers developed a tool for predicting the prognosis of people with chronic lung disease-related pulmonary hypertension.| Pulmonary Hypertension News
A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a study found.| Pulmonary Hypertension News
NORD has launched a U.S. study called Living Rare to capture the lived experiences of rare disease patients and identify changing unmet needs.| Pulmonary Hypertension News
The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of pulmonary hypertension.| Pulmonary Hypertension News
Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
Read about the reasons for the development of pulmonary hypertension (PH).| Pulmonary Hypertension News
INOpulse is a portable device by Bellerophon Therapeutics that supplies pulses of nitric oxide, being tested to treat forms of pulmonary hypertension.| Pulmonary Hypertension News
In hypoxic pulmonary hypertension, exosomes derived from stem cells may be a therapy option for preventing abnormal muscle cell growth.| Pulmonary Hypertension News
Early treatment with iNO and pulmonary surfactant reduces the risk of developing BPD associated with PH in preterm infants, a study found.| Pulmonary Hypertension News
Sensydia has completed a development study of its Cardiac Performance System device to detect pulmonary hypertension and heart failure.| Pulmonary Hypertension News
Sensydia reports completing a 5th study supporting algorithms for its Cardiac Performance System to quickly detect pulmonary hypertension.| Pulmonary Hypertension News
Supporters will unite on May 5 to mark World Pulmonary Hypertension Day, with a focus this year on early diagnosis.| Pulmonary Hypertension News
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Pulmonary Hypertension News
Looking for reliable information on Thromboembolic Pulmonary Hypertension? Find out everything you need to know here.| Pulmonary Hypertension News
Looking for information about pulmonary venous hypertension? PVH's causes, symptoms, diagnosis, and treatments are highlighted here.| Pulmonary Hypertension News
Read about the methods and difficulties to diagnose the lung disease pulmonary hypertension (PH).| Pulmonary Hypertension News
Mutations in certain genes can cause or increase the likelihood of someone developing PAH. This is known as familial or heritable PAH.| Pulmonary Hypertension News
No description.| Pulmonary Hypertension News
Increasing irisin, found at lower levels in people with PAH, may help slow disease progression by stopping vascular remodeling, per a study.| Pulmonary Hypertension News
Platelets tend to cluster in lung blood vessels in people with decompensated pulmonary hypertension, increasing their risk of bleeding, a study says.| Pulmonary Hypertension News
Adding more lines of treatment may reduce the risk of rehospitalization among adults with PAH who are taking only one medication, per a study.| Pulmonary Hypertension News
Many patients with heart dysfunction have pulmonary hypertension, more so if they have enlarged hearts or irregular heartbeats, per a study.| Pulmonary Hypertension News
Pulmonary arterial hypertension (PAH) is a rare type of pulmonary hypertension that can be the result of one of several causes, or by no apparent cause. Read more information about PAH here.| Pulmonary Hypertension News
Using a machine-learned algorithm, Corvista's system can accurately diagnose pulmonary hypertension in a noninvasive way, a study shows.| Pulmonary Hypertension News
Some of the common symptoms of pulmonary hypertension include shortness of breath, excessive fatigue, weakness, chest pain, and fainting.| Pulmonary Hypertension News
Category archive page for News.| Pulmonary Hypertension News
Lindsey Shapiro is a science writer for Pulmonary Hypertension News with a PhD in neuroscience. She covers the latest news and information on a variety of pulmonary hypertension topics.| Pulmonary Hypertension News
A combination treatment may improve survival in patients with both pulmonary hypertension and pulmonary fibrosis, a study found.| Pulmonary Hypertension News
Category archive page for Columns.| Pulmonary Hypertension News
A pivotal study testing Sensydia's noninvasive device, which may help diagnose pulmonary hypertension, enrolled its first participant.| Pulmonary Hypertension News
Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.| Pulmonary Hypertension News
Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.| Pulmonary Hypertension News
Pulmonary hypertension (PH) is a chronic and progressive disease associated with high blood pressure in the blood vessels that supply the lungs, known as the pulmonary arteries. Read more about PH here.| Pulmonary Hypertension News